Your browser doesn't support javascript.
loading
Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552].
Ros, J; Matito, J; Villacampa, G; Comas, R; Garcia, A; Martini, G; Baraibar, I; Saoudi, N; Salvà, F; Martin, Á; Antista, M; Toledo, R; Martinelli, E; Pietrantonio, F; Boccaccino, A; Cremolini, C; Dienstmann, R; Tabernero, J; Vivancos, A; Elez, E.
Afiliação
  • Ros J; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain; Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Matito J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Villacampa G; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; The Institute of Cancer Research, London, UK.
  • Comas R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Garcia A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martini G; Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
  • Baraibar I; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Saoudi N; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Salvà F; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martin Á; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain.
  • Antista M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Toledo R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martinelli E; Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
  • Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Boccaccino A; Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Cremolini C; Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Dienstmann R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Tabernero J; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vivancos A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Elez E; Medical Oncology Department, Vall d'Hebron Hospital Campus, Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: meelez@vhio.net.
Ann Oncol ; 35(10): 922, 2024 Oct.
Article em En | MEDLINE | ID: mdl-39138097
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article